NCT06382103 Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
| NCT ID | NCT06382103 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2024-05-15 |
| Primary Completion | 2025-05-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2024-05-15 with a primary completion date of 2025-05-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
Eligibility Criteria
Inclusion Criteria: * Patients with a first diagnosis of HCC. * Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy. * Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level. Exclusion Criteria: * Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma. * Any other concurrent malignancy. * History of organ transplant or hepatic encephalopathy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06382103 clinical trial?
This trial is open to participants of all sexes, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06382103 currently recruiting?
Yes, NCT06382103 is actively recruiting participants. Contact the research team at sun.huichuan@zs-hospital.sh.cn for enrollment information.
Where is the NCT06382103 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06382103 clinical trial?
NCT06382103 is sponsored by Shanghai Zhongshan Hospital. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.